다중 질병이 발병하는 인지장애 겪는 노인에게 치료법은 무엇인가요?

아세틸콜린 과다는 기관지염 COPD를 유발한다.

치매약물은 아세틸콜린을 인체 내에서 분해되지 못하도록 합니다. 몸에는 아세틸콜린이 넘쳐나게 되어 아세틸콜린을 생산하는 아세틸콜린 리셉터가 작동하기 어렵게 됩니다. 바이러스성 질환을 대비하는 인체 내 면역 물질은 인터페론입니다. 인터페론을 생산하는 아세틸콜린receptor은 이제 작동할 수 없는 지경에 이르게 되었습니다. 계속해서 치매약물을 노인들에게 복용 시킨 결과 소록도의 한센인에게는 기관지염과 COPD가 급증하게 되었습니다.

Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea - Naunyn-Schmiedeberg's Archives of Pharmacology

연구 책임자는 치매약물 부작용에 대한 자세한 정보를 접하게 되었고 약물 부작용에 대하여 연구하였습니다. 또한 치매관리법 입법 과정을 세밀하게 조사했으며 서울대학교병원에서 런칭한 치매약물을 개발한 일본 제약사와 개발자에 대한 추적 연구도 수행하였습니다.

The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea - Naunyn-Schmiedeberg's Archives of Pharmacology

본 연구는 코호트 연구로서 15년 관찰 연구를 통해서 알츠하이머병 치료제를 검증하였습니다.

Dapsone is an anticatalysis for Alzheimer’s disease exacerbationHealth sciences; Biological sciences; Neuroscience; Clinical neuroscience

알츠하이머병 치료 중 발생하는 뇌졸중 뇌경색 연구

The Neuroinflammasome in Alzheimer’s Disease and Cerebral StrokeAbstract. Aim/Background: This review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. Methods: We monitored AD’s progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state. Results: By introducing (D), AD’s progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct. Conclusions: AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24–55 h in the Seoul Study cohort.

최초의 경도인지장애 치료 및 알츠하이머병 치료 케이스 보고 논문

Recovery of Dementia Syndrome following Treatment of Brain InflammationAbstract. Aim/Background: This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer’s disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports, Mycobacterium leprae was a factor in reducing the incidence of Alzheimer’s disease. Thus, we formed a hypothesis that if dapsone is administered to patients without leprosy but with MCI and the prophylactic effect of dementia syndrome is observed over a long period of time, we can determine whether dapsone can prevent the progression of MCI to dementia syndrome. If dementia does not occur after treating inflammation in brain cells while dementia develops after a certain long-term period (usually within 2–3 years), brain cell inflammation can be demonstrated as the cause of dementia. Methods: This is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer’s disease. The patient took Aricept for the treatment of Alzheimer’s disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018. Results: The patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons. Conclusions:This finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer’s disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer’s disease.

e-book

경도인지장애와 치매, 알츠하이머병 치료기

play.google.com/store/books/details?id=m3ZjEAAAQBAJ

Soon Joe's MemorialOnly one person fought the neuro-inflammasome. And many people are preventing the disease. 그리운 어머니 (1931.12.09-2021.01.03.) 어머니는 다행히 92세까지 여한 없이 치료 받으시고 돌아가셨습니다. 기간 중 어머니 진료와 치료 및 자문 등으로 도와주시고 살펴주셔서 감사했습니다. 어머니의 헌신과 질병과 싸우신 용기가 미 헌트병원 진료진의 노력으로 코비드 19 치료 예방의약품을 발견하였고 현재 중환자실 ARDS 환자 20명을 살리셨으며

Page updated

Report abuse